Saxenda specifically licensed for weight management) Dulaglutide (Trulicity, licensed only for diabetes, not weight management) Tirzepatide (Mounjaro), a dual GLP-1 and GIP receptor agonist licensed for type 2 diabetes These medications are administered via subcutaneous injection, typically weekly or daily depending on the specific formulation
Nevertheless, uncritical enthusiasm is unwarranted given the pervasive heterogeneity of existing trials, the profound dependence of therapeutic effects on formulation characteristics, and the inherent limitations of predominantly short-duration interventions in a disease defined by decades of progressive metabolic deterioration
Semaglutide interacted with circumventricular organs, where GLP-1R expression is abundant, and with regions protected by the BBB (lateral septal nucleus, nucleus tractus solitarius, hypothalamic arcuate nucleus) (102)
JACC 82(9):833955 Rangaswami J, Bhalla V, de Boer IH, Staruschenko A, Sharp JA, Singh RR et al (2020) Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association
